Shanghai Pharmaceuticals Holding Co. Ltd
Research Shanghai Pharmaceuticals Holding Co. Ltd (S1R) on Bullrun: valuation model: 61.5% undervalued, market cap EUR 4.78B, P/E 6.5, dividend yield 3.8%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerS1R
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryMedical Distribution
- CurrencyEUR
- Valuation signal61.5% undervalued
- Market capEUR 4.78B
- P/E6.5
- Dividend yield3.8%
- Financial periodQ1 2026
- RevenueEUR 75.26B
- Net incomeEUR 1.42B
- Free cash flow-EUR 1.70B
- Gross margin10.8%
Valuation Snapshot
Bullrun's latest valuation model marks Shanghai Pharmaceuticals Holding Co. Ltd as 61.5% undervalued; latest market cap is EUR 4.78B; P/E is 6.5; dividend yield is 3.8%.
About Shanghai Pharmaceuticals Holding Co. Ltd
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others.
Frequently asked questions
Is Shanghai Pharmaceuticals Holding Co. Ltd overvalued or undervalued?
Bullrun's valuation model currently marks Shanghai Pharmaceuticals Holding Co. Ltd as 61.5% undervalued.
What is Shanghai Pharmaceuticals Holding Co. Ltd's market cap?
Shanghai Pharmaceuticals Holding Co. Ltd's market capitalization is EUR 4.78B.
What is Shanghai Pharmaceuticals Holding Co. Ltd's P/E ratio?
Shanghai Pharmaceuticals Holding Co. Ltd's price-to-earnings (P/E) ratio is 6.5.
Does Shanghai Pharmaceuticals Holding Co. Ltd pay a dividend?
Shanghai Pharmaceuticals Holding Co. Ltd has a dividend yield of 3.8%.
What does Shanghai Pharmaceuticals Holding Co. Ltd do?
Shanghai Pharmaceuticals Holding Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical and healthcare products in China and internationally. The company operates through four segments: Production, Distribution, Retail, and Others.